Diametric Capital LP Has $255,000 Stake in Astera Labs, Inc. $ALAB

Diametric Capital LP reduced its stake in shares of Astera Labs, Inc. (NASDAQ:ALAB) by 58.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,821 shares of the company’s stock after selling 4,040 shares during the period. Diametric Capital LP’s holdings in Astera Labs were worth $255,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. LPL Financial LLC increased its holdings in shares of Astera Labs by 51.0% during the 1st quarter. LPL Financial LLC now owns 82,128 shares of the company’s stock valued at $4,901,000 after acquiring an additional 27,726 shares during the last quarter. Harbour Investments Inc. boosted its position in Astera Labs by 351.7% during the first quarter. Harbour Investments Inc. now owns 795 shares of the company’s stock worth $47,000 after purchasing an additional 619 shares during the period. PNC Financial Services Group Inc. grew its holdings in Astera Labs by 11.9% during the first quarter. PNC Financial Services Group Inc. now owns 5,268 shares of the company’s stock valued at $314,000 after purchasing an additional 560 shares during the last quarter. Blair William & Co. IL bought a new position in shares of Astera Labs in the first quarter valued at approximately $515,000. Finally, Atria Wealth Solutions Inc. lifted its stake in shares of Astera Labs by 81.1% in the first quarter. Atria Wealth Solutions Inc. now owns 4,543 shares of the company’s stock worth $271,000 after buying an additional 2,034 shares during the last quarter. Institutional investors own 60.47% of the company’s stock.

Insider Transactions at Astera Labs

In other news, Director Manuel Alba sold 150,000 shares of the firm’s stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $166.18, for a total transaction of $24,927,000.00. Following the completion of the transaction, the director directly owned 1,574,498 shares of the company’s stock, valued at approximately $261,650,077.64. This trade represents a 8.70% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, General Counsel Philip Mazzara sold 10,000 shares of Astera Labs stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $192.16, for a total transaction of $1,921,600.00. Following the sale, the general counsel owned 151,573 shares in the company, valued at approximately $29,126,267.68. This trade represents a 6.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 586,936 shares of company stock valued at $89,331,140 over the last 90 days. Corporate insiders own 12.50% of the company’s stock.

Astera Labs Stock Performance

NASDAQ ALAB opened at $161.23 on Friday. Astera Labs, Inc. has a twelve month low of $47.13 and a twelve month high of $262.90. The stock has a market cap of $27.23 billion, a PE ratio of 145.25, a PEG ratio of 3.00 and a beta of 1.51. The firm has a 50-day simple moving average of $170.02 and a 200 day simple moving average of $151.11.

Astera Labs (NASDAQ:ALAB) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.39 by $0.10. Astera Labs had a return on equity of 13.48% and a net margin of 27.50%.The firm had revenue of $230.58 million for the quarter, compared to analyst estimates of $206.42 million. During the same period in the previous year, the company posted $0.23 earnings per share. The company’s quarterly revenue was up 103.9% compared to the same quarter last year. Astera Labs has set its Q4 2025 guidance at 0.50-0.510 EPS. Research analysts forecast that Astera Labs, Inc. will post 0.34 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ALAB has been the topic of a number of research analyst reports. Weiss Ratings reiterated a “hold (c-)” rating on shares of Astera Labs in a research note on Wednesday, October 8th. Wall Street Zen downgraded Astera Labs from a “buy” rating to a “hold” rating in a research report on Tuesday, November 11th. Cowen reiterated a “hold” rating on shares of Astera Labs in a research note on Wednesday, November 5th. Morgan Stanley reissued an “overweight” rating and set a $210.00 price objective on shares of Astera Labs in a research report on Wednesday. Finally, BNP Paribas began coverage on Astera Labs in a report on Thursday, November 20th. They issued an “outperform” rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $187.06.

Astera Labs Profile

Astera Labs, Inc designs, manufactures, and sells semiconductor-based connectivity solutions for cloud and AI infrastructure. Its Intelligent Connectivity Platform is comprised of a portfolio of data, network, and memory connectivity products, which are built on a unifying software-defined architecture that enables customers to deploy and operate high performance cloud and AI infrastructure at scale.